It represents the term of agreement.

No definition available.

Name:	iova_AgreementTerm
Namespace Prefix:	iova_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount required to be remitted under the collaborative arrangement .

+ References

No definition available.

+ Details

Name:	iova_CollaborativeArrangementAmountRequiredToBeRemitted
Namespace Prefix:	iova_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Period within which the company is required to be remit the specified amount under the collaborative arrangement.

+ References

No definition available.

+ Details

Name:	iova_CollaborativeArrangementPeriodToRemitRequiredAmount
Namespace Prefix:	iova_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The amortization of milestone payments.

+ References

No definition available.

+ Details

Name:	iova_LicenseAgreementAmortizationOfMilestonePayment
Namespace Prefix:	iova_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of milestone payment made during the period under the license agreement.

+ References

No definition available.

+ Details

Name:	iova_LicenseAgreementMilestonePayment
Namespace Prefix:	iova_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of milestone payments payable under the license agreement.

+ References

No definition available.

+ Details

Name:	iova_LicenseAgreementMilestonePaymentsPayable
Namespace Prefix:	iova_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The percent of milestone payments reimbursable by deduction from deferred consideration.

+ References

No definition available.

+ Details

Name:	iova_LicenseAgreementPercentOfMilestonePaymentsReimbursable
Namespace Prefix:	iova_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	iova_LicensesAndAgreementsLineItems
Namespace Prefix:	iova_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The required notification period before the party may terminate the agreement.

+ References

No definition available.

+ Details

Name:	iova_NotificationPeriodToTerminateAgreement
Namespace Prefix:	iova_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of historical asset purchase agreement.

+ References

No definition available.

+ Details

Name:	iova_NumberOfHistoricalAssetPurchaseAgreement
Namespace Prefix:	iova_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of historical license agreement.

+ References

No definition available.

+ Details

Name:	iova_NumberOfHistoricalLicenseAgreement
Namespace Prefix:	iova_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of historical master cell bank license and working cell bank transfer agreement.

+ References

No definition available.

+ Details

Name:	iova_NumberOfHistoricalMasterCellBankLicenseAndWorkingCellBankTransferAgreement
Namespace Prefix:	iova_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

The number of suites under the agreement.

+ References

No definition available.

+ Details

Name:	iova_NumberOfSuitesUnderAgreement
Namespace Prefix:	iova_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of expenses related to initiation of patient dosing, recorded during the period.

+ References

No definition available.

+ Details

Name:	iova_PatientDosingInitiationExpenses
Namespace Prefix:	iova_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-18

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479532/912-730-25-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=iova_SecondMinarisManufacturingAndServicesAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=iova_PatentLicenseAgreementRelatedToDevelopmentAndManufactureOfTilTherapiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=iova_SecondAmendedAndRestatedPatentLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=iova_PatentLicenseAgreementRelatedToPhase2ClinicalStudyInMelanomaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=iova_CooperativeResearchAndDevelopmentAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=iova_CellectisS.aMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=iova_NovartisPharmaAgAndRelatedEntitiesLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementGeographicalAxis=country_US
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

LICENSES AND AGREEMENTS (Details)		1 Months Ended		3 Months Ended		6 Months Ended		12 Months Ended
LICENSES AND AGREEMENTS (Details)	May 18, 2023 USD ($) item	Jul. 31, 2024	Aug. 31, 2011	Jun. 30, 2026 USD ($)	Jun. 30, 2025 USD ($)	Jun. 30, 2026 USD ($)	Jun. 30, 2025 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2020 USD ($)
LICENSES AND AGREEMENTS
Research and development				$ 58,851,000	$ 77,928,000	$ 121,338,000	$ 153,895,000
Second Minaris Manufacturing and services agreement
LICENSES AND AGREEMENTS
Research and development					6,100,000	$ 6,200,000	14,500,000
Number of suites under the agreement						2
Patent License Agreements Related to TIL Cell Therapies
LICENSES AND AGREEMENTS
Amount of collaborative arrangement required to be remitted				1,500,000		$ 1,500,000
Period of collaborative arrangement required to be remitted						60 days
License agreement				200,000	200,000	$ 400,000	400,000
Second Amended and Restated Patent License Agreement
LICENSES AND AGREEMENTS
Amount of collaborative arrangement required to be remitted				6,000,000		$ 6,000,000
Period of collaborative arrangement required to be remitted						60 days
Phase 2 Clinical Study in Melanoma
LICENSES AND AGREEMENTS
Amount of collaborative arrangement required to be remitted								$ 600,000
Period of collaborative arrangement required to be remitted								60 days
Cooperative Research and Development Agreement
LICENSES AND AGREEMENTS
Agreement term		5 years	5 years
Notification period to terminate agreement		60 days
Research and development				800,000	800,000	$ 1,700,000	1,700,000
Cellectis S.A
LICENSES AND AGREEMENTS
Research and development					100,000	100,000	200,000
Novartis Pharma AG and Related Entities - License Agreement
LICENSES AND AGREEMENTS
Research and development									$ 10,000,000
Patient dosing initiation expenses				0	2,500,000	0	2,500,000
Number of historical asset purchase agreement \| item	2
Number of historical master cell bank license and working cell bank transfer agreement \| item	1
Number of historical license agreement \| item	1
Percent of milestone payments reimbursable	25.00%
Amount of milestone payment made during the period under the license agreement				$ 0	$ 0	$ 0	$ 0
Novartis Pharma AG and Related Entities - License Agreement \| Maximum \| UNITED STATES
LICENSES AND AGREEMENTS
Amount of milestone payments payable under the license agreement	$ 30,000,000
Novartis Pharma AG and Related Entities - License Agreement \| Maximum \| Non-US
LICENSES AND AGREEMENTS
Amount of milestone payments payable under the license agreement	$ 15,000,000